Green Cross, TaKaRa Bio to develop new cancer immunotherapy

Published: 2007-09-12 06:58:00

Updated: 2007-09-12 06:58:00

Korea Green Cross Corporation has signed an agreement with TaKaRa Bio Inc., an innovative biotechnology company based in Shiga, Japan, for the joint development and commercialization of new immunotherapy using TaKaRa Bio's RetroNectin technology.

RetroNectin, TaKaRa Bio's proprietary recombinant protein of human fibronectin, has been widely used for retroviral gene therapy protocols as it si...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.